Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
129.6 USD | -0.57% | +0.58% | +18.83% |
05-07 | CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab) | CI |
05-02 | Merck: encouraging results in gastric cancer | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.83% | 330B | |
+33.55% | 700B | |
-4.95% | 358B | |
+3.31% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+5.72% | 161B | |
-1.98% | 157B | |
+3.70% | 124B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised